Hydroxyl Radical Protein Footprinting: A Mass Spectrometry-Based Structural Method for Studying the Higher Order Structure of Proteins
Hydroxyl radical protein footprinting (HRPF) coupled to mass spectrometry has been efficiently used to analyze a plethora of protein-related questions. The tactic, which makes use of hydroxyl radicals to oxidatively modify solvent-accessible amino acids, can inform on protein interplay websites and areas of conformational change.
Hydroxyl radical-based footprinting was initially developed to review nucleic acids, however coupling the tactic with mass spectrometry has enabled the research of proteins. The tactic has undergone a number of developments since its inception which have elevated its utility for extra diversified purposes corresponding to protein folding and the research of biotherapeutics.
As well as, current improvements have led to the research of more and more complicated techniques together with cell lysates and intact cells. Technological advances have additionally elevated throughput and allowed for higher management of experimental situations. On this assessment, we offer a short historical past of the sector of HRPF and element current improvements and purposes within the area.
Missense mutations involvement in COX-2 construction, and protein-substrate binding affinity: in-silico research
Cyclooxygenase-2 (COX-2) is an inducible inflammatory enzyme, which produces prostanoids from arachidonic acid. COX-2 overexpression and over-activity may cause irritation, tumorigenesis, and angiogenesis. Prostanoids are the primary motive for the irritation, and enhance of mitogenesis by COX-2.
So, any change corresponding to mutations that may result in COX-2 over-activity may ignite the tumor conditions with enhance of prostanoids manufacturing is considered one of its methods. The goal of this research was to test the impact of 166 missense mutations of COX-2 on protein options that may have an effect on the COX-2 exercise corresponding to protein stability, fluctuation, 2D construction, and its binding affinity with the substrate by in silico strategies, community modeling, and docking calculations, by which 44 of them proven to be deleterious.
Amongst them, the S124I and S474F mutations can enhance the soundness of the protein. 11.36% of deleterious nsSNPs have been a part of the substrate-binding area amongst which the M508T, H337R, and V511G have the potential to have an effect on the protein by 2D construction alteration.
V511G can enhance binding affinity and H337R confirmed a small lower within the deformation total vitality that may symbolize a lower within the stability of COX-2. Additionally, L517S confirmed a major lower within the binding energy of COX-2/substrate however primarily based on the anisotropic community modeling this mutation has a twin impact on COX-2 stability. These nsSNPs/mutations have the potential inflicting a rise or lower of tumorigenesis as a result of rising of COX-2 stability and its binding affinity can result in altering its exercise.
Cryo-EM construction willpower of small proteins by nanobody-binding scaffolds (Legobodies)
We describe a common methodology that permits construction willpower of small proteins by single-particle cryo-electron microscopy (cryo-EM). The tactic relies on the supply of a target-binding nanobody, which is then rigidly connected to 2 scaffolds: 1) a Fab fragment of an antibody directed in opposition to the nanobody and a pair of) a nanobody-binding protein A fraction fused to maltose binding protein and Fab-binding domains.
The general ensemble of ∼120 kDa, referred to as Legobody, doesn’t perturb the nanobody-target interplay, is well recognizable in EM pictures because of its distinctive form, and facilitates particle alignment in cryo-EM picture processing.
The utility of the tactic is demonstrated for the KDEL receptor, a 23-kDa membrane protein, leading to a map at 3.2-Å total decision with density enough for de novo mannequin constructing, and for the 22-kDa receptor-binding area (RBD) of SARS-CoV-2 spike protein, leading to a map at 3.6-Å decision that permits evaluation of the binding interface to the nanobody. The Legobody strategy thus overcomes the present dimension limitations of cryo-EM evaluation.
Human Surfactant Protein SP-A1 and SP-A2 Variants Differentially Have an effect on the Alveolar Microenvironment, Surfactant Construction, Regulation and Perform of the Alveolar Macrophage, and Animal and Human Survival Underneath Numerous Circumstances
The human innate host protection molecules, SP-A1 and SP-A2 variants, differentially have an effect on survival after an infection in mice and in lung transplant sufferers. SP-A interacts with the sentinel innate immune cell within the alveolus, the alveolar macrophage (AM), and modulates its perform and regulation.
SP-A additionally performs a task in pulmonary surfactant-related points, together with surfactant construction and reorganization. For many (if not all) pulmonary illnesses there’s a dysregulation of host protection and inflammatory processes and/or surfactant dysfunction or deficiency. As a result of SP-A performs a task in each of those common processes the place one or each might turn out to be aberrant in pulmonary illness, SP-A stands to be an essential molecule in well being and illness.
In people (in contrast to in rodents) SP-A is encoded by two genes (SFTPA1 and SFTPA2) and every has been recognized with in depth genetic and epigenetic complexity. On this assessment, we deal with practical, structural, and regulatory variations between the 2 SP-A gene-specific merchandise, SP-A1 and SP-A2, and amongst their corresponding variants.
We focus on the differential impression of those variants on the surfactant construction, the alveolar microenvironment, the regulation of epithelial kind II miRNome, the regulation and performance of the AM, the general survival of the organism after an infection, and others. Though there have been numerous critiques on SP-A, that is the primary assessment that gives such a complete account of the variations between human SP-A1 and SP-A2.
Advanced construction of the acyltransferase VinK and the service protein VinL with a pantetheine cross-linking probe
Acyltransferases are answerable for the choice and loading of acyl items onto service proteins in polyketide and fatty-acid biosynthesis. Regardless of the significance of protein-protein interactions between the acyltransferase and the service protein, structural info on acyltransferase-carrier protein interactions is proscribed due to the transient interactions between them.
Within the biosynthesis of the polyketide vicenistatin, the acyltransferase VinK acknowledges the service protein VinL for the switch of a dipeptidyl unit. The crystal construction of a VinK-VinL covalent complicated fashioned with a 1,2-bismaleimidoethane cross-linking reagent has been decided beforehand.
Right here, the crystal construction of a VinK-VinL covalent complicated fashioned with a pantetheine cross-linking probe is reported at 1.95 Å decision. Within the construction of the VinK-VinL-probe complicated, the pantetheine probe that’s connected to VinL is covalently linked to the aspect chain of the mutated Cys106 of VinK.
 Recom Protein) Sars-Cov, Spike (N-Term) Recom Protein |
|||
| abx060657-1mg | Abbexa | 1 mg | EUR 1873 |
|
|||
 Anti-SARS-CoV-2 Spike S1 Antibody |
|||
| A3000-50 | Biovision | 50 µg | EUR 419 |
) Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
| P1519-10 | Biovision | 10µg | EUR 156 |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
| P1519-50 | Biovision | 50µg | EUR 551 |
) Recombinant SARS-CoV Spike protein [GST] (37 kDa) |
|||
| VAng-Wyb8620-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: SARS-CoV C-terminal of the Spike protein (37 kDa), recombinant protein from E. coli, 1 mg/mL. |
|||
) Recombinant SARS-CoV Spike protein [GST] (38 kDa) |
|||
| VAng-Wyb8621-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: SARS-CoV middle region of the Spike protein (38 kDa), recombinant protein from E. coli, 1 mg/mL. |
|||
) Recombinant Coronavirus Spike Protein (SARS-CoV-2; ECD) |
|||
| P1533-10 | Biovision | 10 µg | Ask for price |
Recombinant Coronavirus Spike Protein (SARS-CoV-2; ECD) |
|||
| P1533-50 | Biovision | 50 µg | Ask for price |
 SARS-CoV-2 Spike RBD protein antibody pair 1 |
|||
| CSB-EAP33245 | Cusabio | 1 pair | EUR 750 |
|
|||
|
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA. |
|||
) Anti-SARS-CoV-2 Spike S1 Antibody (Clone# 4C6) |
|||
| A3001-50 | Biovision | 50 µg | EUR 419 |
) Recombinant Coronavirus Spike Protein (SARS-CoV S1; His tag) |
|||
| P1516-10 | Biovision | 10µg | EUR 257 |
) Recombinant Coronavirus Spike Protein (SARS-CoV S, His tag) |
|||
| P1520-10 | Biovision | 10µg | EUR 257 |
) Recombinant SARS-CoV-2 Spike Protein S1 (His-tag) |
|||
| P1540-10 | Biovision | 10 µg | EUR 176 |
Recombinant SARS-CoV-2 Spike Protein S1 (His-tag) |
|||
| P1540-50 | Biovision | 50 µg | EUR 682 |
) Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag) |
|||
| P1541-10 | Biovision | 10 µg | EUR 176 |
Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag) |
|||
| P1541-50 | Biovision | 50 µg | EUR 682 |
) Recombinant Coronavirus Spike Protein (SARS-CoV-2; His tag) |
|||
| P1528-10 | Biovision | 10 µg | Ask for price |
Recombinant Coronavirus Spike Protein (SARS-CoV-2; His tag) |
|||
| P1528-50 | Biovision | 50 µg | Ask for price |
 SARS Spike Antibody |
|||
| 24216-100ul | SAB | 100ul | EUR 390 |
SARS Spike Antibody |
|||
| 24217-100ul | SAB | 100ul | EUR 390 |
SARS Spike Antibody |
|||
| 24218-100ul | SAB | 100ul | EUR 390 |
SARS Spike Antibody |
|||
| 24219-100ul | SAB | 100ul | EUR 390 |
SARS Spike Antibody |
|||
| 24318-100ul | SAB | 100ul | EUR 390 |
SARS Spike Antibody |
|||
| 20-abx137184 | Abbexa |
|
|
|
|||
SARS Spike Antibody |
|||
| 20-abx137200 | Abbexa |
|
|
|
|||
, Recombinant) Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant |
|||
| P1530-10 | Biovision | 10 µg | EUR 156 |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant |
|||
| P1530-50 | Biovision | 50 µg | EUR 591 |
, Recombinant) Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2), Recombinant |
|||
| P1547-10 | Biovision | 10 μg | EUR 196 |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2), Recombinant |
|||
| P1547-50 | Biovision | 50 μg | EUR 652 |
, Recombinant) Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant |
|||
| P1555-10 | Biovision | 10μg | EUR 196 |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant |
|||
| P1555-50 | Biovision | 50μg | EUR 591 |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant |
|||
| P1531-10 | Biovision | 10 µg | Ask for price |
Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant |
|||
| P1531-50 | Biovision | 50 µg | Ask for price |
) Recombinant Coronavirus Spike Protein (SARS-CoV S2; 408-470, 540-573) |
|||
| P1518-10 | Biovision | 10µg | EUR 156 |
Recombinant Coronavirus Spike Protein (SARS-CoV S2; 408-470, 540-573) |
|||
| P1518-50 | Biovision | 50µg | EUR 551 |
, Recombinant) Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S1), Recombinant |
|||
| P1524-10 | Biovision | 10 µg | EUR 277 |
, Recombinant) Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S2), Recombinant |
|||
| P1525-10 | Biovision | 10 µg | EUR 277 |
, Recombinant) Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant |
|||
| P1529-10 | Biovision | 10 µg | Ask for price |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant |
|||
| P1529-50 | Biovision | 50 µg | Ask for price |
 SARS CoV E Protein |
|||
| abx060650-1mg | Abbexa | 1 mg | EUR 1692 |
|
|||
 SARS CoV Nucleocapsid Protein |
|||
| abx060652-1mg | Abbexa | 1 mg | EUR 1873 |
|
|||
 SARS-CoV Nucleocapsid Protein |
|||
| abx060653-1mg | Abbexa | 1 mg | EUR 1692 |
|
|||
SARS-CoV Nucleocapsid Protein |
|||
| abx060654-1mg | Abbexa | 1 mg | EUR 1692 |
|
|||
, Recombinant) Human CellExp™ SARS-CoV-2 Spike Protein (S1; His-tag), Recombinant |
|||
| P1532-10 | Biovision | 10 µg | EUR 156 |
Human CellExp™ SARS-CoV-2 Spike Protein (S1; His-tag), Recombinant |
|||
| P1532-50 | Biovision | 50 µg | EUR 551 |
, Recombinant) Human CellExp™ SARS-CoV-2 Spike Protein (RBD 310-568), Recombinant |
|||
| P1543-10 | Biovision | 10 µg | EUR 156 |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD 310-568), Recombinant |
|||
| P1543-50 | Biovision | 50 µg | EUR 480 |
, Recombinant) Human CellExp™ SARS-CoV-2 Spike Protein (RBD; 331-524), Recombinant |
|||
| P1544-10 | Biovision | 10 µg | EUR 156 |
Human CellExp™ SARS-CoV-2 Spike Protein (RBD; 331-524), Recombinant |
|||
| P1544-50 | Biovision | 50 µg | EUR 480 |
 Anti-SARS-CoV-2 Antibody |
|||
| A2061-50 | Biovision | 50 µg | EUR 480 |
) Recombinant Coronavirus Nucleoprotein (SARS-CoV) |
|||
| P1509-10 | Biovision | 10µg | EUR 551 |
 SARS CoV-2 PCR kit |
|||
| PCR-H731-48R | Bioingentech | 48T | EUR 823 |
SARS CoV-2 PCR kit |
|||
| PCR-H731-96R | Bioingentech | 96T | EUR 1113 |
 Recombinant SARS SARS-CoV Protein, His, E.coli-1mg |
|||
| QP13423-1mg | EnQuireBio | 1mg | EUR 3954 |
 Recombinant SARS SARS-CoV Protein, His, E.coli-20ug |
|||
| QP13423-20ug | EnQuireBio | 20ug | EUR 201 |
 Recombinant SARS SARS-CoV Protein, His, E.coli-5ug |
|||
| QP13423-5ug | EnQuireBio | 5ug | EUR 155 |
) Recombinant Coronavirus Spike Protein (SARS-CoV S1; 12-53, 90-115, 171-203) |
|||
| P1515-10 | Biovision | 10µg | EUR 156 |
Recombinant Coronavirus Spike Protein (SARS-CoV S1; 12-53, 90-115, 171-203) |
|||
| P1515-50 | Biovision | 50µg | EUR 551 |
) Recombinant Coronavirus Spike Protein (SARS-CoV S2; 408-470, 540-573, His Tag) |
|||
| P1517-10 | Biovision | 10µg | EUR 257 |
 Recombinant 2019-nCoV coronavirus Spike protein S1 subunit |
|||
| Spike-191V | Creative-Biomart | 100ug | EUR 792 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to His tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
Recombinant 2019-nCoV coronavirus Spike protein S1 subunit |
|||
| Spike-192V | Creative-Biomart | 100ug | EUR 792 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to to Human IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
Recombinant 2019-nCoV coronavirus Spike protein S1 subunit |
|||
| Spike-193V | Creative-Biomart | 100ug | EUR 1610 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to to Mouse IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
 Anti-MERSC-CoV Spike Protein antibody |
|||
| STJ140102 | St John's Laboratory | 150 µg | EUR 231 |
|
Description: Goat polyclonal to Spike protein of Middle East respiratory Syndrome coronavirus. Coronaviruses access host cells by membrane fusion, a process mediated by specific fusion or “spike” proteins on the virion, often activated by cellular proteases. |
|||
) Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022) |
|||
| A2103-200 | Biovision | 200 µg | EUR 480 |
 Recombinant 2019-nCoV coronavirus Spike protein, S1+S2 ECD |
|||
| Spike-194V | Creative-Biomart | 100ug | EUR 1610 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein (S1+S2 ECD) was fused to His-tag at C-terminus and expressed in Baculovirus-Insect cell. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell.S1 mainly contains a receptor binding domain (RBD) and recognize the cell surface receptor. S2 essential for membrane fusion. S protein are important for neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
 Recombinant SARS Coronavirus Spike, GST-Tagged |
|||
| DAG534 | Creative Diagnostics | 1mg | EUR 1556 |
 SARS Associated Spike Mosaic S Protein |
|||
| 20-abx260156 | Abbexa |
|
|
|
|||
 Mouse Monoclonal Anti-SARS Spike IgG |
|||
| AB-17910 | Alpha Diagnostics | 50 ug | EUR 469 |
 Recombinant SARS Spike gp C Protein |
|||
| VAng-Lsx0072-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: SARS Spike glycoprotein C, recombinant protein from E. coli. |
|||
 SARS-CoV-2 Antigen ELISA Kit |
|||
| DEIA2020 | Creative Diagnostics | 96 tests | EUR 905 |
|
|||
|
Description: SARS-CoV-2 Antigen ELISA Kit intended use is for quantitative detection of the recombinant SARS-COV-2 nucleoprotein antigen in human serum. The use of this kit for natural samples need to be validated by the end user due to the complexity of natural targets and unpredictable interference. |
|||
 Recombinant SARS-CoV E Protein [GST] |
|||
| VAng-Wyb8616-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: SARS-CoV E Protein ( 34.7 kDa), recombinant protein from E. coli, 1 mg/mL. |
|||
 SARS-CoV-2 IgG ELISA Kit |
|||
| E4901-100 | Biovision | 100 assays | EUR 753 |
) Recombinant Coronavirus Nucleoprotein (SARS-CoV-2) |
|||
| P1523-10 | Biovision | 10 µg | EUR 156 |
Recombinant Coronavirus Nucleoprotein (SARS-CoV-2) |
|||
| P1523-50 | Biovision | 50 µg | EUR 551 |
) Recombinant Coronavirus Envelope Protein (SARS-CoV) |
|||
| P1534-10 | Biovision | 10 µg | EUR 156 |
Recombinant Coronavirus Envelope Protein (SARS-CoV) |
|||
| P1534-50 | Biovision | 50 µg | EUR 551 |
 SARS CoV-2 RT PCR kit |
|||
| RTq-H731-100R | Bioingentech | 100T | EUR 1311 |
SARS CoV-2 RT PCR kit |
|||
| RTq-H731-150R | Bioingentech | 150T | EUR 1787 |
SARS CoV-2 RT PCR kit |
|||
| RTq-H731-50R | Bioingentech | 50T | EUR 963 |
 Recombinant 2019-nCoV coronavirus Spike protein S1 subunit receptor binding domain |
|||
| Spike-19V | Creative-Biomart | 100ug | EUR 792 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit receptor binding domain (RBD) was fused to Mouse IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
 Recombinant 2019-nCoV coronavirus Spike protein, S1 subunit, expressed in Baculovirus-Insect cells |
|||
| Spike-195V | Creative-Biomart | 100ug | EUR 1610 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to His-tag at C-terminus and expressed in Baculovirus-Insect cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell.S1 mainly contains a receptor binding domain (RBD) and recognize the cell surface receptor. S2 essential for membrane fusion. S protein are important for neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
 Recombinant 2019-nCoV coronavirus Spike protein, S2 ECD, expressed in Baculovirus-Insect cells |
|||
| Spike-197V | Creative-Biomart | 100ug | EUR 1610 |
|
|||
|
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein (S2 ECD) was fused to His-tag at C-terminus and expressed in Baculovirus-Insect cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell.S1 mainly contains a receptor binding domain (RBD) and recognize the cell surface receptor. S2 essential for membrane fusion. S protein are important for neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
) Recombinant SARS Associated Spike Mosaic S(N) |
|||
| 7-07093 | CHI Scientific | 100µg | Ask for price |
Recombinant SARS Associated Spike Mosaic S(N) |
|||
| 7-07094 | CHI Scientific | 500µg | Ask for price |
Recombinant SARS Associated Spike Mosaic S(N) |
|||
| 7-07095 | CHI Scientific | 1000µg | Ask for price |
) Recombinant SARS Associated Spike Mosaic S(M) |
|||
| 7-07096 | CHI Scientific | 100µg | Ask for price |
Recombinant SARS Associated Spike Mosaic S(M) |
|||
| 7-07097 | CHI Scientific | 500µg | Ask for price |
Recombinant SARS Associated Spike Mosaic S(M) |
|||
| 7-07098 | CHI Scientific | 1000µg | Ask for price |
 Recombinant SARS Associated Spike Mosaic S© |
|||
| 7-07099 | CHI Scientific | 100µg | Ask for price |
Recombinant SARS Associated Spike Mosaic S© |
|||
| 7-07100 | CHI Scientific | 500µg | Ask for price |
Recombinant SARS Associated Spike Mosaic S© |
|||
| 7-07101 | CHI Scientific | 1000µg | Ask for price |
) anti-SARS spike glycoprotein antibody (clone 3A2) |
|||
| 65-101 | Sceti | 50ug | EUR 296 |
|
Description: The anti-SARS spike glycoprotein antibody (clone 3A2) is available in Europe and for worldwide shipping via Gentaur. |
|||
 Protein) SARS Associated Spike Mosaic S(M) Protein |
|||
| 20-abx260155 | Abbexa |
|
|
|
|||
 Protein) SARS Associated Spike Mosaic S(N) Protein |
|||
| 20-abx260157 | Abbexa |
|
|
|
|||
 Mouse Monoclonal Anti-SARS Spike Protein IgG |
|||
| AB-15710 | Alpha Diagnostics | 20 ug | EUR 408 |
 SARS Associated Spike Mosaic S) Recombinant (E.Coli) SARS Associated Spike Mosaic S |
|||
| RP-1422 | Alpha Diagnostics | 100 ug | EUR 286 |
The interplay interface between VinK and VinL is actually the identical within the two VinK-VinL complicated buildings, though the place of the pantetheine linker barely differs. This structural statement means that interface interactions usually are not affected by the cross-linking technique used.
